Clinical Trial Update: Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial investigating flexible oral ziprasidone dosing in children and adolescents with Bipolar I Disorder was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder in Children and Adolescents

Drugs mentioned

• Ziprasidone (ziprasidone)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Bipolar Disorder | Phase 3 | Status: TERMINATED | Results posted: 2021-04-01